Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

497 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Assessment of diagnostic criteria for multifocal motor neuropathy in patients included in the Italian database.
Doneddu PE, Gentile L, Cocito D, Fazio R, Luigetti M, Briani C, Filosto M, Siciliano G, Benedetti L, Antonini G, Matà S, Marfia GA, Inghilleri M, Manganelli F, Cosentino G, Brighina F, Carpo M, Carta F, Mazzeo A, Peci E, Strano C, Romano A, Campagnolo M, Cotti-Piccinelli S, Viola DV, Germano F, Leonardi L, Sperti M, Mataluni G, Ceccanti M, Spina E, Vegezzi E, Di Stefano V, Nobile-Orazio E. Doneddu PE, et al. Among authors: antonini g. Eur J Neurol. 2024 May;31(5):e16248. doi: 10.1111/ene.16248. Epub 2024 Feb 20. Eur J Neurol. 2024. PMID: 38376074
A nationwide retrospective analysis on the effect of immune therapies in patients with chronic inflammatory demyelinating polyradiculoneuropathy.
Cocito D, Paolasso I, Antonini G, Benedetti L, Briani C, Comi C, Fazio R, Jann S, Matà S, Mazzeo A, Sabatelli M, Nobile-Orazio E; Italian Network for CIDP Register. Cocito D, et al. Among authors: antonini g. Eur J Neurol. 2010 Feb;17(2):289-94. doi: 10.1111/j.1468-1331.2009.02802.x. Epub 2009 Oct 23. Eur J Neurol. 2010. PMID: 19863650
Regional variation of Guillain-Barré syndrome.
Doets AY, Verboon C, van den Berg B, Harbo T, Cornblath DR, Willison HJ, Islam Z, Attarian S, Barroso FA, Bateman K, Benedetti L, van den Bergh P, Casasnovas C, Cavaletti G, Chavada G, Claeys KG, Dardiotis E, Davidson A, van Doorn PA, Feasby TE, Galassi G, Gorson KC, Hartung HP, Hsieh ST, Hughes RAC, Illa I, Islam B, Kusunoki S, Kuwabara S, Lehmann HC, Miller JAL, Mohammad QD, Monges S, Nobile Orazio E, Pardo J, Pereon Y, Rinaldi S, Querol L, Reddel SW, Reisin RC, Shahrizaila N, Sindrup SH, Waqar W, Jacobs BC; IGOS Consortium. Doets AY, et al. Brain. 2018 Oct 1;141(10):2866-2877. doi: 10.1093/brain/awy232. Brain. 2018. PMID: 30247567 Free article.
Impact of 2021 European Academy of Neurology/Peripheral Nerve Society diagnostic criteria on diagnosis and therapy of chronic inflammatory demyelinating polyradiculoneuropathy variants.
De Lorenzo A, Liberatore G, Doneddu PE, Manganelli F, Cocito D, Briani C, Fazio R, Mazzeo A, Schenone A, Di Stefano V, Cosentino G, Marfia GA, Benedetti L, Carpo M, Filosto M, Antonini G, Clerici AM, Luigetti M, Matà S, Rosso T, Lucchetta M, Siciliano G, Lauria Pinter G, Cavaletti G, Inghilleri M, Cantisani T, Notturno F, Ricciardi D, Habetswallner F, Spina E, Peci E, Salvalaggio A, Falzone Y, Strano C, Gentile L, Vegezzi E, Mataluni G, Cotti Piccinelli S, Leonardi L, Romano A, Nobile-Orazio E; Italian CIDP Database Study Group. De Lorenzo A, et al. Among authors: antonini g. Eur J Neurol. 2024 Apr;31(4):e16190. doi: 10.1111/ene.16190. Epub 2024 Jan 2. Eur J Neurol. 2024. PMID: 38165011
Chronic inflammatory demyelinating polyneuropathy and HEV antibody status: A case-control study from Lazio, Italy.
Moret F, Spada E, Ceccanti M, Libonati L, D'Andrea E, Villano U, Madonna E, Chionne P, Carocci A, Pisani G, Fionda L, Antonini G, Petrucci A, Bruni R, Ciccaglione AR, Taliani G, Rivano Capparuccia M, Nobile-Orazio E, Inghilleri M, Cambieri C. Moret F, et al. Among authors: antonini g. J Neurol Sci. 2024 Apr 15;459:122959. doi: 10.1016/j.jns.2024.122959. Epub 2024 Mar 12. J Neurol Sci. 2024. PMID: 38490091 Free article.
Current treatment practice of Guillain-Barré syndrome.
Verboon C, Doets AY, Galassi G, Davidson A, Waheed W, Péréon Y, Shahrizaila N, Kusunoki S, Lehmann HC, Harbo T, Monges S, Van den Bergh P, Willison HJ, Cornblath DR, Jacobs BC; IGOS Consortium. Verboon C, et al. Neurology. 2019 Jul 2;93(1):e59-e76. doi: 10.1212/WNL.0000000000007719. Epub 2019 Jun 7. Neurology. 2019. PMID: 31175208 Free article.
International Guillain-Barré Syndrome Outcome Study: protocol of a prospective observational cohort study on clinical and biological predictors of disease course and outcome in Guillain-Barré syndrome.
Jacobs BC, van den Berg B, Verboon C, Chavada G, Cornblath DR, Gorson KC, Harbo T, Hartung HP, Hughes RAC, Kusunoki S, van Doorn PA, Willison HJ; IGOS Consortium. Jacobs BC, et al. J Peripher Nerv Syst. 2017 Jun;22(2):68-76. doi: 10.1111/jns.12209. J Peripher Nerv Syst. 2017. PMID: 28406555 Free article.
Original research: Second IVIg course in Guillain-Barré syndrome with poor prognosis: the non-randomised ISID study.
Verboon C, van den Berg B, Cornblath DR, Venema E, Gorson KC, Lunn MP, Lingsma H, Van den Bergh P, Harbo T, Bateman K, Pereon Y, Sindrup SH, Kusunoki S, Miller J, Islam Z, Hartung HP, Chavada G, Jacobs BC, Hughes RAC, van Doorn PA; IGOS Consortium. Verboon C, et al. J Neurol Neurosurg Psychiatry. 2020 Feb;91(2):113-121. doi: 10.1136/jnnp-2019-321496. Epub 2019 Oct 5. J Neurol Neurosurg Psychiatry. 2020. PMID: 31586949
Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study.
Howard JF Jr, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, Jacob S, Vissing J, Burns TM, Kissel JT, Muppidi S, Nowak RJ, O'Brien F, Wang JJ, Mantegazza R; REGAIN Study Group. Howard JF Jr, et al. Lancet Neurol. 2017 Dec;16(12):976-986. doi: 10.1016/S1474-4422(17)30369-1. Epub 2017 Oct 20. Lancet Neurol. 2017. PMID: 29066163 Clinical Trial.
Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial.
van Schaik IN, Bril V, van Geloven N, Hartung HP, Lewis RA, Sobue G, Lawo JP, Praus M, Mielke O, Durn BL, Cornblath DR, Merkies ISJ; PATH study group. van Schaik IN, et al. Lancet Neurol. 2018 Jan;17(1):35-46. doi: 10.1016/S1474-4422(17)30378-2. Epub 2017 Nov 6. Lancet Neurol. 2018. PMID: 29122523 Free article. Clinical Trial.
497 results